IMCRImmunocore Holdings PLC - ADR
$27.90
$0.62
(2.17%)
Closed $27.90
$0.00
(0.00%)
After Hours
EarningsAug 6
Mkt Cap$1.45B
Vol318,096.00
Fundamentals
Mkt Cap
$1.45B
Volume
-
52W High
$40.71
52W Low
$27.56
PE Ratio
-50.84
Avg. Volume
345,551.77
EPS (Annual)
-$0.707
Rev/Employee
$765,173.26
Earnings
Aug 06
Eli Lilly Wins FDA Nod for Extended Ebglyss Dosing in Eczema Care
LLY wins FDA approval for every-8-week Ebglyss maintenance dosing in eczema, reducing injections per year while maintaining long-term disease control.
Zacks
TGTX Rises on Positive Phase I Data for Subcutaneous Briumvi in MG
TG Therapeutics gains after positive phase I data for subcutaneous Briumvi in myasthenia gravis or MG, while a phase II study in MG gets underway.
Zacks
Sanofi Ends Late-Stage Study on Neurology Drug Over Weak Results
SNY halts its phase III MOBILIZE study after an interim review finds riliprubart unlikely to deliver sufficient efficacy in refractory CIDP patients.
Zacks
ARGX Shares Gain Nearly 9% in a Month: Here's What You Need to Know
argenx stock rises nearly 9% in a month after the FDA expands Vyvgart's gMG label, opening treatment to adult patients regardless of antibody status.
Zacks
Incyte to Buy Vega Therapeutics in Hematology Deal Worth Up to $2B
Incyte will acquire Vega Therapeutics for up to $2B, adding late-stage VWD candidate VGA039 and expanding its hematology growth prospects.
Zacks
J&J to Expand Cancer Pipeline With $1B Firefly Bio Acquisition
JNJ is set to acquire Firefly Bio for $1 billion in cash, adding its Firelink DAC platform and advancing efforts in KRAS-driven cancer treatments.
Zacks
PFE Gets FDA Nod for Expanded Use of Hemophilia Drug Hympavzi
Pfizer wins FDA approval to expand Hympavzi's use in additional hemophilia A and B patient groups, including children with inhibitors.
Zacks
CORT Stock Rises 42% in a Month: Here's What You Should Know
Corcept shares surge 42% in a month as relacorilant advances in Cushing's syndrome and Lifyorli approval to expand the company's revenue base.
Zacks
Novo Nordisk Real-World Data Supports Ozempic Against LLY's Mounjaro
NVO says real-world data show Ozempic 2 mg matches Eli Lilly's Mounjaro on glucose control and is linked to a higher likelihood of meaningful weight loss.
Zacks
ALVO Stock Gains 19% on FDA Resubmission of Biosimilar BLAs
Alvotech shares surge after the company resubmits FDA applications for its biosimilar candidates, AVT05 and AVT06, with reviews expected within six months.
Zacks
<
1
2
...
>